Semax: A Neurotrophin Signal in a Heptapeptide

The short version

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It combines the active fragment of adrenocorticotropic hormone (ACTH(4-7), the four amino acids Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro tail that slows enzymatic degradation. Crucially, it retains none of the cortisol-releasing activity of full-length ACTH. Its most consistently documented effect in rodent brain is a rapid, region-specific upregulation of the neurotrophins BDNF and NGF ^[10][11].

Here is the honest part. Almost all of the mechanistic and efficacy data comes from Russian institutions and Ukrainian clinical practice, largely in stroke and cognitive-impairment models. There are no published Western randomized controlled trials of Semax for any indication. In Russia and Ukraine it is a prescription medicine; in the United States it is an unscheduled research chemical. This page summarizes the published science; it is not advice and lists no human dose.

What it is

Semax is also catalogued as ACTH(4-7)PGP, MEHFPGP (its one-letter amino-acid sequence), and sometimes as Met-ACTH(4-7)-Pro-Gly-Pro. It is commonly supplied as the acetate salt.

The parent sequence ACTH(4-7) is a fragment of the pituitary hormone adrenocorticotropin. The key distinction from full-length ACTH is that Semax lacks the domains responsible for stimulating the adrenal cortex to produce cortisol — so it does not raise cortisol levels. The Pro-Gly-Pro tail is borrowed from a different family of neuroprotective peptides and is there primarily to extend the half-life of the otherwise rapidly degraded parent fragment.

Outside Russia and Ukraine, Semax is not an approved drug in any major Western jurisdiction and is sold only as a research chemical.

How it works

Semax's effects in rodent models are attributed to three overlapping mechanisms.

Neurotrophin upregulation. The best-characterized effect is rapid, region-specific induction of neurotrophin gene and protein expression. A single intranasal dose in rats raised NGF and BDNF mRNA in the hippocampus, BDNF in the brainstem and cerebellum, while NGF mRNA fell in frontal cortex — showing that the response is gene-specific and region-specific rather than a global neurotrophin surge ^[10]. A companion study found a rapid, region-specific rise in BDNF protein in the rat basal forebrain (but not cerebellum) 3 hours after intranasal dosing, and identified a specific, reversible, calcium-dependent binding site with a dissociation constant of 2.4 nM — the first binding site characterized for Semax ^[11].

Immunomodulatory and vascular gene expression in ischemia. Genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion in rats showed that Semax predominantly modified immune-system genes (more than 50% of affected genes, including immunoglobulins and chemokines) and vascular-system genes. This frames immunomodulation and vascular regulation, rather than a single receptor action, as the core mechanism of its neuroprotective effect ^[9].

Enkephalin stabilization and monoaminergic effects. Semax inhibited enkephalin-degrading enzymes in human serum in vitro (IC50 approximately 10 micromolar), proposing a route by which it prolongs endogenous opioid-peptide signaling. In rodent studies it also raised the serotonin metabolite 5-HIAA and strongly potentiated amphetamine-evoked dopamine release, without raising baseline dopamine on its own [see controversies for this nuance].

What the research shows

Spinal cord injury in mice (2025). In female C57BL/6 mice with T9-T10 spinal-cord injury, Semax improved locomotor recovery and reduced lysosomal-membrane-permeabilization-related pyroptosis, acting via the mu-opioid receptor gene Oprm1 through regulation of USP18 and deubiquitination of the FTO protein ^[8]. This is the most recent mechanistic study in the index and opens a new axis — opioid-receptor-linked neuroprotection — distinct from the neurotrophin story.

Transcriptomic neuroprotection in focal ischemia (rats, 2014). Genome-wide analysis after permanent MCAO showed that Semax's protective effect is dominated by a large-scale immune and vascular gene-expression shift: more than 50% of affected genes were immune-related, and 24 vascular-system genes were altered at 3 hours (12 at 24 hours) ^[9]. This positions immunomodulation as the core of its ischemic neuroprotection, not a single receptor.

NGF and BDNF mRNA induction (rats, 2007). A single 50 microg/kg intranasal dose produced rapid, gene- and region-specific changes: NGF and BDNF mRNA rose in hippocampus, BDNF rose in brainstem and cerebellum, while NGF mRNA fell in frontal cortex. The pattern was direction-specific per region, not a global rise ^[10].

BDNF protein and specific binding site (rats, 2006). Intranasal Semax at 50 and 250 microg/kg produced a rapid, region-specific increase in BDNF protein in rat basal forebrain (but not cerebellum) 3 hours after dosing. A specific, reversible, Ca2+-dependent binding site was identified with KD 2.4 nM and Bmax 33.5 fmol/mg protein — the first evidence of a dedicated binding site for Semax ^[11].

Neuroprotection and antiamnesic effect in cortical ischemia (rats, 2006). Intranasal Semax given for 6 days in a focal photoinduced prefrontal-cortex ischemia model decreased cortical infarct volume and improved retention of a conditioned passive-avoidance response ^[12].

Reported effects, cautions & safety

The following community reports are compiled from nootropic forums, biohacker writeups, and peptide-user communities. They are anecdotal, not clinical evidence, and are presented separately from the cited research findings above.

What users commonly report (anecdotal):

• Fast, clean mental clarity — The single most consistent report is a quick-onset sense of clear-headedness, often within the first hour. People describe thoughts as more organized and mental fog lifting, contrasted explicitly with the jittery quality of caffeine or stimulants.
• Sustained focus and task-completion drive — Users describe staying locked onto a task for longer and looking back at the end of a day noticing more got done. Described as quiet productivity rather than a euphoric push.
• Stimulant-free motivation and energy — Many report motivation and physical energy rising for several hours without feeling overstimulated.
• Improved verbal fluency and word recall — A recurring and fairly distinctive report is that conversation gets easier, vocabulary feels richer, and words come faster.
• Mood lift and stress resilience — A modest acute bump in mood and a more even-keeled feeling are commonly reported, with some describing reduced negative rumination.
• Non-response is common — Many people say Semax is "not a nootropic you feel," that any benefit is subtle and only obvious in hindsight, and some report essentially nothing. Expectations of a dramatic effect are frequently disappointed.
• Short duration of effect — The noticeable effect is commonly described as lasting a few hours before tapering.
• Nasal irritation, burning, or congestion — Because the most common route is intranasal, burning, stinging, or congestion right after dosing is frequently mentioned. Most describe it as fading within 10 to 15 minutes.

Cited cautions from the literature:

• Unregulated sourcing. In the US, Semax is sold only as an unscheduled research chemical with no required testing of identity, purity, or sterility.
• Limited long-term human safety data outside Russian and Ukrainian use. Human experience and clinical evidence are largely confined to Russian and Ukrainian practice; there are no FDA- or EMA-approved indications and no published Western randomized controlled trials ^[9][11][12].
• Intranasal route irritates the nasal lining. Repeated application of a research-grade solution carries potential for mucosal irritation beyond what any published study assessed in research populations ^[12].
• Unknown drug interactions, especially with stimulants and antidepressants. Semax raised the serotonin metabolite 5-HIAA in rodents and strongly potentiated amphetamine-evoked dopamine release; combining it with stimulants, serotonergic antidepressants, or opioid-active drugs carries unstudied and potentially additive risks ^[8][11].
• Neurotrophin and gene-expression effects are powerful and incompletely understood. Rapidly changing BDNF, NGF, and large numbers of immune and vascular genes in a healthy brain over months or years has not been studied ^[9][10][11].
• No established human dosing, cycling, or tolerance framework. All quantitative dosing in the literature is from animal studies in rats and mice, and community cycling practices are not backed by characterized pharmacokinetics ^[12].
• Not FDA-approved. Classified as an unscheduled research chemical in the US; a prescription drug only in Russia and Ukraine for stroke and cognitive impairment.

Where it fits in cognitive research

Of the two peptides on this desk, Semax is the more neuroprotection-oriented. Where Selank addresses anxiety and emotional tone directly via GABAergic and enkephalin mechanisms, Semax operates through neurotrophin biology and immune-gene expression — mechanisms that become most visible in injury models rather than in healthy-brain anxiety. Its preclinical record is coherent and mechanistically interesting; its human evidence base is real but regionally narrow and not independently replicated. Together, Selank and Semax offer two entry points into the cognitive peptide literature from different directions. See the comparison page for the side-by-side.